Fig. 5
Talazoparib plus decitabine treatment significantly impair growth of BRCA mutant xenografts and PDX. A M231wt xenografts. B SUM149PT xenografts. C M231BRCA2 xenografts. D PDX TM00089, n = 6 animals per group. E PDX TM00091. A, B, C, E n = 5 animals per group. A–F Xenografts recieved 0.1 mg/kg talazoparib (Cat. #S7048, SelleckChem®) given by oral gavage or carrier, and/or 0.2 mg/kg decitabine (Cat. #S1200, SelleckChem®) or carrier given by intraperitoneal (IP) injection. PDX received the identical talazoparib dose, and ½ dose of decitabine. Treatment schedule for all mice was 5-days on/2-days off. A–E Values indicate mean ± SEM. Significance determined by two-way ANOVA with Tukey’s adjustment for multiple testing. ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.1; ns, not significant. E final tumor images for TM00091; #, animal died 2 days before tumor harvests, tumor was unrecoverable